58982 Federal Register / Vol. 62, No. 211 / Friday, October 31, 1997 / Notices

respondents, 20 hours average response

time.

(6) An estimate of the total public

burden (in hours) associated with this

collection: 60,000 hours annually.

If additional information is required

contact: Mr. Robert B. Briggs, Clearance

Officer, United States Department of

Justice, Information Management and

Security Staff, Justice Management

Division, Suite 850, Washington Center,

1001 G Street, NW., Washington, DC

20530.

Dated: October 27, 1997.

Robert B. Briggs,

Department Clearance Officer, United States

Department of Justice.

[FR Doc. 97–28857 Filed 10–30–97; 8:45 am]

BILLING CODE 4410–26–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National

Cooperative Research and Production

Act of 1993—Inter Company

Collaboration for Aids Drug

Development

Notice is hereby given that, on

September 15, 1997, pursuant to Section

6(a) of the National Cooperative

Research and Production Act of 1993,

15 U.S.C. § 4301 et seq. (‘‘the Act’’),

Inter Company Collaboration for Aids

Drug Development (The Collaboration)

filed written notifications

simultaneously with the Attorney

General and the Federal Trade

Commission. The notifications were

filed for the purpose of extending the

Act’s provisions limiting the recovery of

antitrust plaintiffs to actual damages

under specified circumstances.

As indicated in its previous filings,

the Collaboration is intended to

facilitate more efficient concomitant and

or comparative research on HIV

antiviral compounds through the

sharing of scientific information among

its members, the sharing of compounds

to conduct appropriate investigations

for clinical research, and the

coordination of certain clinical trials

conducted independently by certain of

its members. A purpose of this filing is

to confirm that these activities of the

Collaboration encompass gene therapy

related to the treatment of HIV infection

and AIDS.

The Collaboration may also engage in

the collection, analysis and exchange of

research information, including

information on statistical techniques

applicable to AIDS research with other

groups or entities engaged in research

on HIV and AIDS, as well as within the

Collaboration.

In addition, the Collaboration may, as

an organization, engage in scientific and

policy discussions with governmental

agencies (including FDA and NIH). This

activity may involve development,

exchange and analysis of scientific

information within the Collaboration,

and presentation, analysis and

discussion by the Collaboration with

government agencies. Such discussions

may include consideration of the

appropriate surrogate markers for

approval of AIDS anti-viral drugs and

innovative statistical techniques to

address issues presented by AIDS drug

clinical trials. This activity may also

involve the development and

presentation of regulatory positions by

the Collaboration to governmental

agencies.

Although no changes have been made

in the membership of the Collaboration,

Collaboration member AJI PHARMA

USA, Inc. has merged with its parent,

Ajinomoto Co., Inc.; Collaboration

member Triangle Pharmaceuticals Inc.

has acquired Avid Corporation by

merger with a subsidiary; and

Collaboration member Ciba-Geigy AG

has merged with Sandoz AG to form

Novartis AG. As a part of the merger

process, the Ciba-Geigy pharmaceutical

operations, including its membership in

the Collaboration, became part of

Novartis Pharma AG, Novartis,

pharmaceutical operating subsidiary.

Membership in the Collaboration

remains open.

On May 27, 1993, the Collaboration

filed its original notification pursuant to

Section 6(a) of the Act. The Department

of Justice published a notice in the

Federal Register pursuant to Section

6(b) of the Act on July 6, 1993 (58 FR

36223). The last notification was filed

with the Department on August 23,

1996. A notice was published in the

Federal Register on September 17, 1996

(61 FR 48982).

Constance K. Robinson,

Director of Operations, Antitrust Division.

[FR Doc. 97–28949 Filed 10–30–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National

Cooperative Research and Production

Act of 1993; National Information

Infrastructure Testbed

Notice is hereby given that, on August

11, 1997, pursuant to Section 6(a) of the

National Cooperative Research and

Production Act of 1993, 15 U.S.C.

§ 4301 et seq. (‘‘the Act’’), National

Information Infrastructure Testbed, Inc.,

d/b/a InfoTEST International

(‘‘InfoTEST’’) has filed written

notifications simultaneously with the

Attorney General and the Federal Trade

Commission disclosing changes in

membership. the notifications were filed

for the purpose of extending the Act’s

provisions limiting the recovery of

antitrust plaintiffs to actual damages

under specified circumstances.

Specifically, Agility Forum-Lehigh

University, and Network & Systems

Consulting are no longer members of

InfoTEST.

No other changes have been made in

the membership, nature, or objectives of

the consortium. Membership in

InfoTEST remains open, and the

consortium intends to file additional

written notifications disclosing all

changes in membership.

On December 7, 1993, InfoTEST filed

its original notification (as the National

Information Infrastructure Testbed)

pursuant to Section 6(a) of the Act. The

Department of Justice published a notice

in the Federal Register pursuant to

Section 6(b) of the Act on May 18, 1994

(60 FR 25,960).

The last notification was filed with

the Department of Justuce on June 10,

1997. A notice for this filing has not yet

been published in the Federal Register.

Constance K. Robinson,

Director of Operations Antitrust Division.

[FR Doc. 97–28953 Filed 10–30–97; 8:45 am]

BILLING CODE 4410–11–M

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National

Cooperative Research and Production

Act of 1993; Portland Cement

Association

Notice is hereby given that, on

September 15, 1997, pursuant to Section

6(a) of the National Cooperative

Research and Production Act of 1993,

15 U.S.C. § 4301 et seq. (‘‘the Act’’), the

Portland Cement Association (‘‘PCA’’)

filed notifications simultaneously with

the Attorney General and the Federal

Trade Commission disclosing (1) a

change in membership and (2) changes

in the names of certain participants. The

notifications were filed for the purpose

of extending the Act’s provisions

limiting the recovery of antitrust

plaintiffs to actual damages under

specified circumstances. Specifically,

effective November 1, 1997, Texas

Industries, Dallas, TX will become a